Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy

The article addresses the use of mavacamten in treating nonobstructive hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy is a disease characterized by abnormal thickening of the heart muscle. The nonobstructive form is distinguished by the fact that the thickened muscle does not block blood flow from the heart. Mavacamten is a drug that affects heart muscle function and its efficacy was investigated in clinical trials. The article was published in the prestigious medical journal New England Journal of Medicine in June 2026. The research represents progress in pharmacological treatment options for this serious cardiac disease.